Efficacy and safety of KN026 in combination with KN046 in patients with locally advanced unresectable or metastatic HER2-positive other solid tumors.
Jifang Gong(Peking University), Lin Shen(Hangzhou Normal University), Jieer Ying(Chinese Academy of Medical Sciences & Peking Union Medical College), Xionghui Li, Xiangcai Wang(First Affiliated Hospital of Gannan Medical University), Meili Sun(Jinan Central Hospital), Lei Chen(Zhuzhou Central Hospital), Yuan Lv, Mingli Ni(Luoyang Central Hospital Affiliated to Zhengzhou University), Rusen Zhao(Central Hospital of Zibo), Yanming Zhang(Memorial Sloan Kettering Cancer Center), Zhixiang Zhuang(Soochow University)
Cited by 6
Related Papers
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Hepatogastroenterology
|Hepatogastroenterology|2012|1.3k
Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma
|New England Journal of Medicine|2019|934